A study demonstrates how heart ... Food Insecurity Today, Heart Disease Tomorrow? Mar. 12, 2025 — Struggling to afford food today could mean heart problems tomorrow. Young adults experiencing ...

Horses change their coat depending on the season — a thick winter coat protects them from the cold, while a shorter coat keeps them cool in summer. But what happens when the coat doesn't change? In ...

Corcept Therapeutics (CORT) announced the initiation of MOMENTUM, a clinical trial examining the prevalence of endogenous ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

What is Guillain-Barré syndrome? Guillain-Barré syndrome (GBS) is also called acute inflammatory demyelinating polyradiculoneuropathy (AIDP). It's a neurological disorder in which the body's immune ...

CORT's Cushing's syndrome drug, Korlym, is driving revenues. The FDA's acceptance of the NDA for relacorilant also bodes well ...

The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for relacorilant to treat patients with Cushing syndrome (hypercortisolism).

Hallmark symptoms of Cushing disease, including abdominal striae and facial rounding, were more common among younger patients than older patients.

Followed categories will be added to My News. It is estimated up to 1600 Australians are living with Cushing’s Disease, with about 41 new cases of the disease diagnosed across the country each year.

It is estimated up to 1600 Australians are living with Cushing’s Disease, with about 41 new cases of the disease diagnosed across the country each year. Osilodrostat (Isturisa), which has been ...